- Home
- INSM vs HBANZ Comparison
INSM vs HBANZ Comparison
Compare INSM & HBANZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INSM | HBANZ |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2B | 33.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INSM | HBANZ |
|---|---|---|
| Price | $140.44 | $21.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $188.73 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 52.9K |
| Earning Date | 05-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $168.46 | N/A |
| Revenue Next Year | $65.97 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $60.40 | $21.17 |
| 52 Week High | $212.75 | $22.23 |
Technical Indicators
Market Signals| Indicator | INSM | HBANZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 49.49 |
| Support Level | $139.81 | $21.27 |
| Resistance Level | $167.01 | $21.83 |
| Average True Range (ATR) | 6.70 | 0.24 |
| MACD | -0.57 | -0.07 |
| Stochastic Oscillator | 0.58 | 8.33 |
Price Performance
Historical ComparisonAbout INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.